From the Journals

Since COVID-19 onset, admissions for MI are down, mortality rates are up


 

FROM JAMA CARDIOLOGY

More than fear of COVID-19?

One theory to account for the reduction in AMI hospitalizations and the increase in AMI-related mortality is the possibility that patients were slow to seek care at acute care hospitals because of concern about COVID-19 infection, according to Dr. Gluckman and coinvestigators.

“Given the time-sensitive nature of STEMI, any delay by patients, emergency medical services, the emergency department, or cardiac catheterization laboratory may have played a role,” they suggested.

In an interview, Dr. Gluckman said that further effort to identify the reasons for the increased AMI-related mortality is planned. Pulling data from the electronic medical records of the patients included in this retrospective analysis might be a “challenge,” but Dr. Gluckman reported that he and his coinvestigators plan to look at a different set of registry data that might provide information on sources of delay, particularly in the STEMI population.

“This includes looking at a number of time factors, such as symptom onset to first medical contact, first medical contact to device, and door-in-door-out times,” Dr. Gluckman said. The goal is to “better understand if delays [in treatment] occurred during the pandemic and, if so, how they may have contributed to increases in risk adjusted mortality.”

Dr. Krumholz, director of the Yale Center for Outcomes Research and Evaluation, New Haven, Conn., called this study a “useful” confirmation of changes in AMI-related care with the onset of the COVID-19 pandemic. As reported anecdotally, the study “indicates marked decreases in hospitalizations of patients with AMI even in areas that were not experiencing big outbreaks but did have some restrictions to limit spread,” he noted.

More data gathered by other centers might provide information about what it all means.

“There remain so many questions about what happened and what consequences accrued,” Dr. Krumholz observed. “In the meantime, we need to continue to send the message that people with symptoms that suggest a heart attack need to rapidly seek care.”

The investigators reported having no financial conflicts of interest.

SOURCE: Gluckman TJ et al. JAMA Cardiol. 2020 Aug 7. doi: 10.1001/jamacardio.2020.3629.

Pages

Recommended Reading

Signature STEMI sign may be less diagnostic in the COVID-19 age
MDedge Endocrinology
Consensus recommendations on AMI management during COVID-19
MDedge Endocrinology
Out-of-hospital cardiac arrests soar during COVID-19 in Italy
MDedge Endocrinology
As visits for AMI drop during pandemic, deaths rise
MDedge Endocrinology
ED visits for life-threatening conditions declined early in COVID-19 pandemic
MDedge Endocrinology
Daily Recap: ED visits for life-threatening conditions plummet; COVID-19 imaging strategies for kids
MDedge Endocrinology
Ultrasound, cardiac CT valuable in COVID-19 assessment
MDedge Endocrinology
Levothyroxine: No LV benefit in subclinical hypothyroidism with MI
MDedge Endocrinology
Most younger MI patients wouldn’t get statins under guidelines
MDedge Endocrinology
AHA on cannabis: No evidence of heart benefits, but potential harms
MDedge Endocrinology